Gilead Sciences

Antibody-drug conjugate
#ADC #Antibodies #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Gilead Sciences #Nucleai #Oncology

Nucleai and Gilead Sciences enter oncology ADC collaboration

Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More

#News

T cells
#Autoimmune disease #Gilead Sciences #Mergers and acquisitions #T cell engagers

Gilead to advance first T cell engager for autoimmune diseases

Gilead Sciences has entered an agreement to acquire Ouro Medicines, a biotechnology company focused on developing T cell engager therapies for autoimmune diseases.  The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s inflammation portfolio.   OM336 is designed to enable… Read More

#Business & Investment #News

Gilead offices
#Advanced Therapies #Arcellx #CAR-T #Cell therapy #Gilead Sciences #Mergers and acquisitions

Gilead Sciences to acquire CAR-T company Arcellx

Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion.   Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases.  The companies have an existing collaboration… Read More

#Business & Investment #News #Trending News

Prostate cancer cells
#Gilead Sciences #Mergers and acquisitions #Oncology #Sprint Bioscience

Gilead buys Sprint Bioscience’s TREX1 cancer programme

Gilead Sciences has acquired the TREX1 cancer programme from Sprint Bioscience for an upfront payment of $14 million plus milestone payments up to $400 million.  The objective of the TREX1 programme, which is in the preclinical phase, is to develop drugs that inhibit the TREX1 protein in… Read More

#Business & Investment #News

HIV cell
#Clinical trial design #Gilead Sciences #HIV #Phase III trial

Yeztugo provides strong HIV protection in diverse patient groups

Gilead Sciences will share new Phase III trial data showing that twice-yearly lenacapavir (Yeztugo) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention.  The new data, from the company’s pivotal Phase III PURPOSE 1 and… Read More

#News

#Acute inflammatory conditions #Gilead Sciences #LEO Pharma #Partnership

Gilead and LEO Pharma join forces against inflammatory diseases

Gilead Sciences and LEO Pharma have agreed a strategic partnership to accelerate the development of LEO Pharma’s small molecule STAT6 programmes for inflammatory diseases.  STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signalling, which are clinically validated targets for Th2 mediated inflammatory conditions… Read More

#Business & Investment #News

HIV cell
#Gilead Sciences #HIV #Phase III trial #Virology

Twice-yearly HIV injection demonstrates 100% efficacy

Interim analysis of the Phase III PURPOSE 1 trial indicates that Gilead Sciences twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrates 100% efficacy for the investigational use of HIV prevention in cisgender women. PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily… Read More

#News #Trending News

Gilead Sciences, Oxford facility
#Acute inflammatory conditions #Gilead Sciences #MiroBio #Research and development #UK

Gilead Sciences opens first research centre outside US

Gilead Sciences has opened a new research site at the Business Park in Oxford, UK. With capacity for up to 60 research scientists and employees, the company says the site will play a role in helping to drive innovation in the UK life sciences sector, with… Read More

#News

Hepatitis B
#Gilead Sciences #hepatitis #HOOKIPA Pharma #Immunology / Virology & Vaccines #Preclinical investigations

Preclinical data supports arenaviral therapeutic vaccine for hepatitis B

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability… Read More

#News

Long Covid
#Antivirals #Burton NHS Foundation Trust #Covid-19 #Gilead Sciences #Long Covid #University Hospitals of Derby #University of Exeter

Could a common antiviral treat long Covid?

A UK-based study will investigate whether a common anti-viral medication could double up as a treatment for long Covid. The project involves teams from the University Hospitals of Derby and Burton NHS Foundation Trust and the University of Exeter, in collaboration with Gilead Sciences. Read More

#News #Trending News

CAR-T therapy
#Blood cancer #CAR-T #Cell therapy #Gilead Sciences #Kite Pharma #National Institute for Health and Care Excellence (NICE) #Oncology

UK’s NICE expands use of CAR-T cell therapy for blood cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with… Read More

#News #Regulatory #Trending News

Vascular endothelial growth factor A
#Drug targets #Gilead Sciences #GlobalData #Krystal Biotech #Neurodegenerative disorders #Regenerative Medicine

Regenerative medicine switches to VEGF as top drug target

Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. According to analysts GlobalData, early-stage therapies are now focused on vascular endothelial growth factor (VEGF) as the top drug target, with three drugs currently in development. Surprisingly, the… Read More

#News #Trends & Analysis

Scotland
#Gilead Sciences #hepatitis #Immunology / Virology & Vaccines #Marketing approval authorisation #Scottish Medicines Consortium (SMC)

Scottish regulator approves first chronic hepatitis delta virus drug

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. The drug has been accepted for the treatment of chronic HDV infection in adult… Read More

#News #Regulatory

Breast cancer treatment
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #FDA #Gilead Sciences #GlobalData #Oncology

ADC potential “standard of care” for some breast cancer patients

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.  The drug is expected to become a standard of care for these patients,… Read More

#News #Trending News